Table 2.

HDAC inhibitors in clinical studies.

HDACIs	Clinical Trial Phase	Clinical Trial ID	Cancer Types	Trial Description	Status	References
MS-275 (Entinostat)	I	NCT00020579	Refractory solid tumors and lymphoid	Well tolerated at a dose of 6 mg/m2, administered weekly with food for 4 weeks every 6 weeks	Completed	[142]
Romidepsin (Depsipeptid)	I	NCT00053963	Solid tumors	Well tolerated in children with refractory solid tumors	Completed	[143]
	II	NCT00106613	Renal cell carcinoma	Did not have sufficient activity.	Completed	[144]
	I	NCT00077337	Colorectal cancer	Romidepsin at dose of 13 mg/m2 as a 4 h iv infusion on days 1, 8, and 15 of a 28-day cycle was ineffective in treatment of metastatic colon cancer	Completed	[133]
Panobinostat (LBH589)	II	NCT00667862	Hormone refractory prostate cancer	Panobinostat did not show a sufficient level of clinical activity to undergo further investigation in CRPC	Completed	[145]
	II	NCT00425555	Cutaneous T-cell lymphoma	Panobinostat was generally well tolerated with no major safety concerns.	Completed	[146]
	I	NCT00412997	Solid tumors	Doses well tolerated up to 20 mg in Japanese patients	Completed	[147]
Belinostat (PXD 101)	I	NCT01273155	Adult primary hepatocellular carcinoma and advanced adult primary liver cancer	Increased belinostat exposure accompanied hepatic dysfunction	Completed	[148]
	I and II	NCT00321594	Localized unresectable adult primary liver cancer and recurrent adult primary liver cancer	Phase I—belinostat tolerated at maximum dose of 1200 mg/m2/day Phase II—will start with 1200 mg/m2/day	Completed	[149]
Vorinostat	I	NCT00097929	Relapsed diffuse large B-cell lymphoma	Limited activity against relapsed DLBCL	Completed	[150]
	II	NCT00132067	Primary peritoneal cavity recurrent ovarian epithelial cancer	Vorinostat well tolerated with minimal activity as a single agent	Completed	[135]